Impact of Maternal Medication Use During Pregnancy on Childhood Cancer Risk

Overview

This comprehensive systematic review and meta-analysis evaluated the association between maternal medication use during pregnancy and the risk of childhood cancers. The study synthesized evidence from multiple observational studies, highlighting the multifactorial etiology of childhood cancers and the potential influence of prenatal medication exposure.

Background

Childhood cancer, though rare, is the leading cause of disease-related death in children over one year of age, with leukemia, lymphomas, and CNS tumors being most common. Genetic predispositions account for only a small fraction of cases, while environmental and lifestyle factors, including prenatal exposures, are implicated in cancer risk. Pregnant women frequently use medications due to infections and other conditions, raising concerns about the impact of these exposures on childhood cancer development. Prior studies have reported inconsistent findings, necessitating a comprehensive meta-analysis to clarify these associations.

Data Highlights

The review included epidemiological studies providing quantitative risk estimates such as odds ratios, relative risks, and hazard ratios for childhood cancer risk associated with prenatal medication exposure. Studies were selected based on rigorous criteria, including exclusion of pre-pregnancy only exposures and diethylstilbestrol use. Quality assessment was performed using an adapted Newcastle–Ottawa Scale combined with ROBINS tools, ensuring robust evaluation of bias and confounding.

Key Findings

• Childhood cancers are predominantly leukemia, lymphomas, and CNS tumors, differing from adult cancer types.
• Genetic factors explain only 5-10% of childhood cancers, highlighting the importance of environmental and prenatal influences.
• Up to 90% of pregnant women use medications, including antibiotics, analgesics, antiemetics, hormones, and vitamin supplements.
• Existing observational studies on prenatal medication use and childhood cancer risk show inconsistent results, underscoring the need for meta-analytic synthesis.
• The systematic review and meta-analysis followed PRISMA and MOOSE guidelines and included studies with quantitative risk estimates to assess associations comprehensively.

Clinical Implications

Clinicians should be aware that while medication use during pregnancy is common and often necessary, its potential impact on childhood cancer risk remains unclear due to inconsistent evidence. Careful consideration of the benefits and risks of prenatal medication use is warranted, and further high-quality research is needed to guide clinical decision-making. Monitoring and minimizing unnecessary medication exposure during pregnancy may be prudent until more definitive data are available.

Conclusion

This systematic review and meta-analysis provide a comprehensive synthesis of current evidence on maternal medication use during pregnancy and childhood cancer risk, emphasizing the multifactorial nature of childhood cancers and the need for cautious interpretation of prenatal medication effects. Further research is essential to clarify these associations and inform clinical practice.

Related Resources & Content

1. Multiple Sources 2022-2025 -- Childhood Cancer Epidemiology and Prenatal Exposure Studies